In brief: Acrux, Meditech, Psivida
Tuesday, 03 May, 2005
Melbourne's Acrux (ASX: ACR) has Adam Watkinson as its chief scientific officer. Watkinson is currently manager of drug delivery research and project manager at UK pharmaceutical company ProStrakan .
Meditech Research's (ASX: MTR) Ian Nisbet is to present the company's business plans and product data at the Rodman & Renshaw Global Healthcare Conference in Paris on May 5.
pSivida Limited (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) is to present the interim data from its Phase IIa BrachySil trial in patients with primary liver cancer to the European Society for Therapeutic and Radiation Oncology Conference in Budapest on May 5.
Psivida has reported that both patient cohorts from the Phase IIa trial show the product is safe and effective in prompting tumour regression.The final data is expected to be released in June.
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
Vaccine for elephant herpesvirus found to be safe
The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...
